* 2,* 4,* 5,* 8,* 9 1: an important caveat for all genotyping tests is that the decision to assign
an allele a “wildtype” status is based upon a genotyping test that interrogates only the most …

Each named* allele is defined by the genotype at one or more specific single-nucleotide
polymorphisms (see Supplementary Table S1—see the «Availability of Companion …

Cytochrome P450 3A4 (CYP3A4) is the most important drug metabolizing enzyme in the
liver, responsible for the oxidative metabolism of∼ 50% of clinically prescribed drugs …

Aim: To test the relevance of revisiting the genotype classification based on CYP3A5* 3
solely by incorporating CYP3A4* 22 information. Methods: Discriminant analysis of principal …

Cytochrome P450 3A4 (CYP3A4) is the most important drug metabolizing enzyme in the
liver, responsible for the oxidative metabolism of∼ 50% of clinically prescribed drugs …

The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature
for the polymorphic human CYP3A5 gene. Genetic variation within the CYP3A5 gene locus …

In many studies of the pharmacogenetic effects of dosing the immunosuppressant drug,
tacrolimus, a single allele of CYP3A5 (* 3) is often the only one considered as it is the most …

The calcineurin inhibitor tacrolimus has become a cornerstone for immunosuppression in
solid organ and hematopoietic stem cell transplant (HCT) over the past four decades. It has …

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and
hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and …

Genetic variability of CYP2C19 may affect safety or efficacy of many clinically important
medications as outlined in the clinical pharmacogenetics implementation consortium (CPIC) …